Spring direct naar de hoofdnavigatie of de inhoud

Jennifer Ebner von Eschenbach

Patent attorney

“Investing that little extra time and effort in IP at the right moment makes your technology go further.”
Home / Experts / Jennifer Ebner von Eschenbach

Jennifer Ebner von Eschenbach

Jennifer Ebner von Eschenbach

  • Chemistry
  • Life Sciences
  • European Patent Attorney
  • Senior Associate

Jennifer Ebner von Eschenbach began her career as a European patent attorney in 1991 when she commenced her training in the Munich office of the international IP law firm of Ladas & Parry, LLP. Jennifer took over the office management from 1996-2008, during which time she was involved with the prosecution of patent applications for many multinational companies and research institutions. This provided her with an insight of IP needs covering a broad technological spectrum.

More information about Jennifer

Since joining V.O. in 2008, Jennifer has focused on developments in the pharmaceutical and chemical sectors, including novel therapies, diagnostic tools, (bio)technological processes for the employment of renewable resources, as well as environmentally-conscious chemical processes/products, again spanning both a broad range of technologies and clients.

Jennifer has a wide practical experience in procuring and defending patents, including the filing and defense of oppositions. Through the provision of opinions on patent validity and infringement, she also has considerable experience in advising on parties’ freedom to operate.

Working experience

  • Patent Attorney, V.O. (2008-present)
  • Patent Attorney, Ladas & Parry, LLP (1991-2008): Manager of office in Munich (1996-2008)
  • Post-Doctoral Research, Inorganic Chemical Institute of the Technical University of Munich (1989-1990)

Education

  • PhD in Chemistry, University of Melbourne (1988)
  • MSc in Chemistry, University of Melbourne (1984, with honours)

Publications

  • •Schmidbaur H., Ebner von Eschenbach J., Kumberger O., & Müller G., Cyclic Dinuclear Gold(I) Complexes: The Crystal Structure of Bis-µ-[(diphenylphosphino)(diphenylphosphinoselenoyl)methane]-digold(I) Bis(perchlorate), Chem. Ber., 123, 2261-2265, 1990
  • Bond A. M., Colton R., Ebner J., & Ellis S. R., Differences in Nature and Stability of Cadmium Complexes with Group 15/Group 16 Donor Ligands as Determined by Multinuclear (31P, 77Se, 113Cd) Magnetic Resonance and Electrochemical Techniques, Inorganic Chemistry, 28, 4509-4516, 1989
  • Colton R., Ebner J., & Hoskins B. F., Multinuclear Magnetic Resonance Studies of the Reactions of Bidentate Ligands with Pt(S2P{OEt}2)2. Crystal and Molecular Structure of (apeS)Pt(S2P{OEt}2)2 (ApeS = Ph2AsCH2CH2P(S)Ph2) , Inorganic Chemistry, 27, 1993-1999, 1988
  • Bond A. M., Colton R., & Ebner J., Multinuclear Magnetic Resonance (31P, 77Se, 199Hg) and Electrochemical Studies of Non-labile Mercury(II) Complexes with Group 15/Group 16 Donor Ligands, Inorganic Chemistry, 27, 1697-1702, 1988

Languages

  • German
  • English

Also see these experts

Bettina Hermann

  • European Patent Attorney
  • German Patent Attorney
  • European and German Trademark and Design Attorney
  • Partner

Marijke Westra

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
More experts

News

The Nagoya Protocol and its impact on your research

The Nagoya Protocol is often believed to apply exclusively to the plant breeding sector. However, the influence of the protocol reaches much further. Almost everyone utilizing genetic resources for research may have to deal with it. From individuals and universities to multinationals in all sectors, everyone needs to check whether their research is covered by […]Continue reading

Childhood dream comes true in the circular economy

They met at Nedstaal and now the three of them are busy getting a revolutionary business off the ground. Purified Metal Company (PMC) in Delfzijl will soon clean contaminated scrap for reuse. Director Jan Henk Wijma: “This is a childhood dream. It began on a sheet of A4 and now we’ve almost come so far […]Continue reading

No happy ending for a pharmaceutical company in a case involving a Native American tribe

In the case known as Mohawk tribe versus Mylan, the US Federal Circuit Court of Appeals ruled that patent holders cannot shield themselves from an “inter partes review” of a patent by assigning that patent to a Native American tribe. Ironically enough, this is due to the fact that the decision handed down by the […]Continue reading

Events

IPPLA 3rd Annual Meeting 2018

Omni Hotel, California Street, San Francisco, Californië, USA

Annual Meeting of International Intellectual Property Law Association, Inc. (IIPLA) is the leading event in the West USA. Attended by hundreds of participants from more than 35+ countries. More about this event

Improve your practical knowledge at the IP Academy – Basic

Winthontlaan 6, 3526 KV Utrecht, Utrecht, Netherlands

Follow the annual course on patents, trademarks and designs. For innovative entrepreneurs who wish to improve their intellectual property (IP) know-how, V.O. Patents & Trademarks organizes a basic course on IP on Thursday 1 November 2018. More about this event

BIO-EUROPE

Bella Center, Center Boulevard, København, Denemarken

BIO-EUROPE brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more. More about this event